

1 **Repeat expansion and methylation state analysis with nanopore**
2 **sequencing**

3 Pay Gießelmann^{§1}, Björn Brändl^{§1,2}, Etienne Raimondeau³, Rebecca Bowen³,
4 Christian Rohrandt⁴, Rashmi Tandon², Helene Kretzmer¹, Günter Assum⁵, Christina
5 Galonska¹, Reiner Siebert⁵, Ole Ammerpohl⁵, Andrew Heron³, Susanne A.
6 Schneider⁶, Julia Ladewig^{7,8,9,10}, Philipp Koch^{7,8,9}, Bernhard M. Schuldt², James E.
7 Graham³, Alexander Meissner^{1,11} and Franz-Josef Müller^{*1,2}

8 **1** Department of Genome Regulation, Max Planck Institute for Molecular Genetics, (Berlin, Germany) **2**
9 Universitätsklinikum Schleswig-Holstein Campus Kiel, Zentrum für Integrative Psychiatrie gGmbH (Kiel,
10 Germany) **3** Oxford Nanopore Technologies (Oxford, UK) **4** Kiel University of Applied Sciences, Institute for
11 Communications Technology and Microelectronics (Kiel, Germany) **5** Institute for Human Genetics, Ulm
12 University and Ulm University Medical Center (Ulm, Germany) **6** Department of Neurology, Ludwig-Maximilians-
13 Universität (München, Germany) **7** Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg
14 University (Mannheim, Germany) **8** HITBR Hector Institute for Translational Brain Research gGmbH (Heidelberg,
15 Germany) **9** German Cancer Research Center (DKFZ) (Heidelberg, Germany) **10** Institute of Reconstructive
16 Neurobiology, University of Bonn Medical Center (Bonn, Germany) **11** Department of Stem Cell and
17 Regenerative Biology, Harvard University (Cambridge, USA)

18 [§] Pay Gießelmann and Björn Brändl contributed equally to this work.


19 * corresponding author

20 **Expansions of short tandem repeats are genetic variants that have been**
21 **implicated in neuropsychiatric and other disorders but their assessment**
22 **remains challenging with current molecular methods. Here, we developed a**
23 **Cas12a-based enrichment strategy for nanopore sequencing that, combined**
24 **with a new algorithm for raw signal analysis, enables us to efficiently target,**
25 **sequence and precisely quantify repeat numbers as well as their DNA**
26 **methylation status. Taking advantage of these single molecule nanopore**
27 **signals provides therefore unprecedented opportunities to study pathological**
28 **repeat expansions.**

29 The expansion of unstable genomic Short Tandem Repeats (STRs) causes more
30 than 30 Mendelian human disorders¹. For example, expansion of a GGGGCC-repeat
31 [(G₄C₂)_n] within the C9orf72 gene is the most frequent monogenic cause of
32 Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS;
33 c9FTD/ALS; OMIM: # 105550)^{2,3}. Similarly, accumulation of a CGG motif in the
34 FMR1 gene underlies the Fragile X Syndrome (FXS; OMIM # 300624), currently the
35 most common identifiable genetic cause of mental retardation and autism⁴. In both
36 prototypical repeat expansion disorders (Suppl. Discussion 1), recent evidence has
37 suggested pronounced inter- and intraindividual repeat variability as well as changes
38 in DNA methylation of the respective genomic regions to modulate disease
39 phenotype⁵⁻⁸.

40 To overcome current difficulties in characterizing expanded STRs (Suppl. Discussion
41 2) most notably we focused on three areas: i) optimization of Nanopore sequencing
42 and signal processing to capture STRs ii) development and implementation of a

43 target enrichment strategy to increase efficiency and iii) integration of expansion
 44 measurements with DNA methylation of the same molecule.



45

46 **Figure1** nanoSTRique: Generic repeat detection pipeline on raw nanopore signals.


47 **a**) Repeat quantification by signal-alignment of flanking prefix and suffix regions and HMM based
 48 count on signal of interest. **b**) BioAnalyzer electropherogram, decoy alignment, RepeatHMM and
 49 nanoSTRique counts of synthetic $(G_4C_2)_n$ repeats (10k random reads per barcode, +/- 10 % intervals
 50 around expected repeat length). **c**) Nanopore sequencing and analysis of BAC clone 239 from a
 51 c9ALS/FTD patient compared to cropped corresponding lane from Ref. 15 for illustration purpose. **d**)
 52 manual confirmation of detected repeat counts in synthetic repeats ($n=16, 50, 49, 49, 47$).

53 First, for benchmarking repeat expansion counting methods we constructed, verified
 54 and nanopore sequenced plasmids with several synthetic $(G_4C_2)_n$ -repeat lengths⁹.
 55 We analyzed our results with currently available STR quantification pipelines^{10,11} but
 56 found those methods to become unreliable for more than 32 $(G_4C_2)_n$ -repeats with
 57 nanopore reads. To further improve the repeat analysis we developed a signal
 58 processing algorithm for a more exact quantification of STR numbers in raw
 59 nanopore signals (nanoSTRique: **n**anopore **S**hort **T**andem **R**epeat **i**dentification,
 60 **q**uantification & **e**valuation, Fig. 1a, Suppl. Fig. 1). Briefly (see Online Methods for
 61 details), reads spanning a STR location are identified by aligning the conventionally
 62 base-called sequences to a reference¹². Next, nanoSTRique maps the upstream and
 63 downstream boundaries of each repeat more precisely with a signal alignment

64 algorithm using SeqAn2¹³ and, as a third step, accurately quantifies the number of
65 any given STR sequence with a Hidden Markov Model (Suppl. Fig. 1)¹⁴. Aggregated
66 nanoSTRique repeat counts matched closely gel electrophoresis profiles from our
67 synthetic repeats and could be confirmed on the single molecule level by manually
68 counting repeat patterns in raw signal traces (Fig. 1d) (Suppl. Fig. 2, 3). Previously,
69 repeat instability had been noted in Bacterial Artificial Chromosomes (BAC)
70 containing expanded C9orf72 (G₄C₂)_n-repeats (Online Methods)¹⁵. Analysing BAC
71 clone 239 from a c9FTD/ALS patient (G₄C₂)_{~800}¹⁵ with nanoSTRique we observed
72 STR contractions in many reads and a secondary peak at 800 repeats (Fig 1c,
73 Online Methods), while existing methods failed to mirror previously published
74 Southern blot results (Suppl. Fig. 3).

75 Next we performed whole genome nanopore sequencing from c9FTD/ALS patient-
76 derived DNA using four MinION flow cells yielding a total of 39 GBp (8M reads, 11
77 on target, none expanded). Our and similar nanopore whole genome sequencing
78 results from others¹⁶ suggested a relevant bias against the detection of (G₄C₂)_n-
79 expansions with conventional molecular and bioinformatic nanopore workflows. To
80 improve the coverage of any STR particularly the (G₄C₂)_n-region in our proof of
81 concept, we took advantage of the programmable CRISPR-Cas12a-
82 ribonucleoprotein (Cas12a-RNP), which cleaves DNA via staggered double-strand
83 breaks¹⁷. The Cas-system was applied to selectively target DNA sequences from a
84 patient-derived induced pluripotent stem cell line (24/5#2) adjacent to the (G₄C₂)_n-
85 repeat resulting in unique 4 bp overhangs amenable to ligation of a linker oligo and
86 subsequent attachment of the nanopore sequencing adapter (Fig. 2a, Online
87 Methods). To further improve enrichment results we replaced the oligo adapter
88 ligation step by adding Klenow fragment to fill in the Cas12a overhangs. The

89 resulting dA-tailed DNA ends enabled even more efficient ligation of the sequencing
 90 adapters.



91

92 **Figure 2** Targeted enrichment and nanopore sequencing with CRISPR-Cas12a.

93 **a)** Illustration of the CRISPR-Cas12a target enrichment procedure **b)** Repeat quantification of sample
 94 24/5#2 on c9orf72 and FMR1 loci revealing two distinct repeat bands of ~450 and ~750 $(G_4C_2)_n$ -
 95 repeats. (n=442,165,78,499; difference in repeat length 385 [95% CI: 361:404]) **c)** c9orf72
 96 methylation status in Hues64 (WGBS), wild type allele and expanded allele of patient 24/5#2
 97 (nanopore). **d)** Single read nanopore methylation of c9orf72 covering reads (n=769, row split 30,500)
 98 sorted by detected repeat length. (row:single read, column: single CpG, log-p > 2.5: methylated, log-p
 99 < -2.5: unmethylated, two sided wilcoxon rank sum test on mean promoter CGI methylation, median
 100 methylation difference [95% CI] wt-450: 6.9e-6 [3.5e-5 - 3.3e-2], wt-750: 0.33 [0.24 - 0.42], 450-750:
 101 0.30 [0.20 - 0.42]) **e)** Repeat quantification of SC105iPS6/iPS7 sample on c9orf72 and FMR1 loci.
 102 (n=850,183,23; difference in repeat length -322 [95% CI: -351:-298]) **f)** FMR1 methylation status in
 103 Hues64 (WGBS), wild type allele of patient 24/5#2 and expanded alleles of samples SC105iPS6 and
 104 SC105iPS7¹⁹ (nanopore). (All box plots show median, box edges represent 1st and 3rd quartiles,
 105 whiskers extend to 1.5 x IQR; two sided wilcoxon rank sum tests, p-val: * 0.05 - 0.01; ** 0.01 - 0.001;
 106 *** < 0.001)

107 Additional dephosphorylation of all 5' ends before Cas12a-RNP-digestion chemically

108 protects DNA 'background' fragments from being ligated to sequencing adapters.

109 Consequently, only those fragments cut by Cas12a-RNPs are capable of being

110 sequenced by this procedure (Fig. 2a). Using this approach we were able to obtain a

111 total of 1137 reads covering the $(G_4C_2)_n$ -repeat including 442 evaluable reads from

112 expanded alleles (Suppl. Table 2, Suppl. Discussion 3). Consistent with Southern

113 blot results from the same cell line (Suppl. Fig. 6 a-d), we found two distinct repeat

114 expansion distributions (Fig. 2b). To explore the general applicability of our
115 enrichment, sequencing and read processing we next tested two isogenic, patient-
116 derived cell lines (SC105iPS6, SC105iPS7) carrying a FMR1-repeat expansion with
117 an additional set of FMR1-targeting Cas12a-RNPs (Suppl. Table 1) and found two
118 different repeat expansion distributions (Fig. 2e).

119 Lastly, epigenetic modification of both C9orf72 and FMR1 loci have been correlated
120 with STR expansion status and patient characteristics in both disorders^{7,8}. We
121 therefore combined single molecule CpG methylation analysis using nanopolish¹⁸
122 with our nanoSTRique results and found that in the 24/5#2 line all reads with STR
123 expansions > 750 repeats showed significantly increased methylation at the
124 promoter CpG island while all wild type reads and those with < 500 repeats were not
125 or only partially methylated (Two sided wilcoxon rank sum test $p < 0,001$, Fig. 2C-D,
126 Suppl. Fig. 4, Suppl. Discussion 4). Similarly, we found all FMR1 wild type alleles
127 enriched from controls were unmethylated at a CpG island overlapping the CGG-
128 STR. Consistent with previous findings¹⁹ and in our Southern blot analyses, all
129 expanded alleles identified by nanoSTRique from both isogenic FXS-patient derived
130 cell lines¹⁹, were determined to be methylated (Fig. 2f, Suppl. Fig. 6f-h).

131 Our results demonstrate the power of nanopore sequencing for the precise and
132 multilayered molecular characterization of pathological short tandem repeat
133 expansions. We have increased the enrichment for regions of interest on the
134 background of the human genome approximately two to three orders of magnitude
135 without any target amplification by using selective, multiplexed Cas12a-based
136 chemical tagging of DNA fragments. Importantly, our method does not require any
137 additional instruments in contrast to other previously reported enrichment

138 strategies²⁰ and enables reporting the DNA methylation status of the same alleles.
139 The Cas12a-target enrichment and nanoSTRique can be rapidly adapted to any
140 other genomic region of interest, ensuring broad applicability to overcome challenges
141 associated with the single molecule analysis integrating genetic and epigenetic
142 signals associated with unstable repeat expansions or any other as of yet
143 'unsequenceable' genomic regions in human health and disease. This type of
144 analysis improves diagnostic workflows in regard to accuracy and resolution of
145 unstable repeat expansion while enabling efforts to gain mechanistic insights into
146 effects on differentiation, aging and future therapeutic agents that modify DNA
147 methylation.

148 7. Acknowledgements

149 We are deeply thankful for the invaluable support by c9FTD/ALS and FXS patients
150 and their families who donated fibroblast for this study. The C9orf72 BAC was
151 generously provided by Robert Baloh and Shaughn Bell (Cedars Sinai Medical
152 Center, Los Angeles, CA, USA). We are grateful to Jeanne Loring and Ai Zhang
153 (The Scripps Research Institute, La Jolla, CA, USA) for providing us with hiPSC lines
154 from a Fragile X patient (Supported by NIH R33MH087925-03). We thank Philip van
155 Damme and Wim Robberecht (Laboratory for Neurobiology; VIB-KU Leuven Center
156 for Brain & Disease Research, Leuven, Belgium) for providing the c9FTD/ALS
157 patient-derived fibroblasts used for reprogramming. We acknowledge the expert
158 assistance of the technical staff of the molecular genetics laboratory of the Institute
159 of Human Genetics, Ulm. PK and JL acknowledge financial support by the Hector
160 Stiftung II gGmbH. This work was supported by the Max Planck Society.

161 8. Author information

162 Contributions:

163 PG, BMS and FJM conceived the project. BB and RT performed cell culture, plasmid
164 and BAC expansion and extraction. PG wrote the nanoSTRique pipeline. PG, BMS,
165 CR, HK conducted additional bioinformatic analyses. PK and JL reprogrammed the
166 c9FTD/ALS hiPSC from patient fibroblasts used in this study. ER, RB, AH, JEG
167 developed the Cas12a-RNP protocol. BB further developed the Cas12a protocol with
168 c9FTD/ALS and FXS patient-derived DNA and performed all nanopore library
169 preparation and nanopore sequencing for the results presented in this manuscript,
170 RT and CG worked on optimization of aspects of the enrichment protocol. GA and
171 RS conducted diagnostic testing of the repeat expansions by Southern Blot and PCR
172 analyses, SS, RS, OA and GA provided clinical and diagnostic advice. PG, BMS, AM
173 and FJM wrote the manuscript. FJM oversaw the study. All authors contributed to the
174 editing and completion of the manuscript.

175 Competing Interests Declaration:

176 ER, RB, AH and JEG are employees of Oxford Nanopore Technologies Ltd (ONT).
177 CR was reimbursed for travel costs for an invited talk at the Nanopore Days 2018 in
178 Heidelberg (Germany) by ONT. ONT had no role in the study design, interpretation
179 of results and writing of the manuscript.

180 9. Data availability

181 All sequencing data points generated in this study (i.e. nanopore reads, raw and
182 base called) and utilized for the determination of FMR1 and C9orf72 repeat

183 expansion lengths and methylation status will be made public upon acceptance
184 through a public repository (e.g. EGA). Whole genome sequencing data generated
185 for this study will be made accessible to researchers upon request under a Data
186 Access Agreement similar to the procedure required for managed access by the
187 European Genome-phenome Archive. (for details see:
188 https://www.ebi.ac.uk/ega/submission/data_access_committee/policy_documentation).

189

- 190 1. Gatchel, J. R. & Zoghbi, H. Y. Diseases of unstable repeat expansion: mechanisms and
191 common principles. *Nat Rev Genet* **6**, 743–755 (2005).
- 192 2. Renton, A. E. *et al.* A hexanucleotide repeat expansion in C9ORF72 is the cause of
193 chromosome 9p21-linked ALS-FTD. *Neuron* **72**, 257–268 (2011).
- 194 3. DeJesus-Hernandez, M. *et al.* Expanded GGGGCC hexanucleotide repeat in noncoding
195 region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* **72**, 245–256 (2011).
- 196 4. Verkerk, A. J. *et al.* Identification of a gene (FMR-1) containing a CGG repeat coincident with a
197 breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell* **65**, 905–914
198 (1991).
- 199 5. van Blitterswijk, M. *et al.* Association between repeat sizes and clinical and pathological
200 characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional
201 cohort study. *Lancet Neuro* **12**, 978–988 (2013).
- 202 6. Xi, Z. *et al.* Hypermethylation of the CpG Island Near the G4C2 Repeat in ALS with a C9orf72
203 Expansion. *The American Journal of Human Genetics* **92**, 981–989 (2013).
- 204 7. Russ, J. *et al.* Hypermethylation of repeat expanded C9orf72 is a clinical and molecular
205 disease modifier. *Acta Neuropathol.* **129**, 39–52 (2015).
- 206 8. Hornstra, L. K., Nelson, D. L., Warren, S. T. & Yang, T. P. High resolution methylation analysis
207 of the FMR1 gene trinucleotide repeat region in fragile X syndrome. *Hum Mol Genet* **2**, 1659–
208 1665 (1993).
- 209 9. Mizielińska, S. *et al.* C9orf72 repeat expansions cause neurodegeneration in Drosophila
210 through arginine-rich proteins. *Science* **345**, 1192–1194 (2014).
- 211 10. Liu, Q., Zhang, P., Wang, D., Gu, W. & Wang, K. Interrogating the ‘unsequenceable’ genomic
212 trinucleotide repeat disorders by long-read sequencing. *Genome Medicine* **2017 9:19**, 65
213 (2017).
- 214 11. Dashnow, H. *et al.* STRetch: detecting and discovering pathogenic short tandem repeat
215 expansions. *Genome Bio* **19**, 121 (2018).
- 216 12. Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **3**, 321 (2018).
- 217 13. Reinert, K. *et al.* The SeqAn C++ template library for efficient sequence analysis: A resource
218 for programmers. *J. Biotechnol.* **261**, 157–168 (2017).
- 219 14. Schreiber, J. & Karplus, K. Analysis of nanopore data using hidden Markov models.
220 *Bioinformatics* **31**, 1897–1903 (2015).
- 221 15. O'Rourke, J. G. *et al.* C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of
222 ALS/FTD. *Neuron* **88**, 892–901 (2015).
- 223 16. Ebbert, M. T. W. *et al.* Long-read sequencing across the C9orf72 ‘GGGGCC’ repeat
224 expansion: implications for clinical use and genetic discovery efforts in human disease. *Mol*
225 *Neurodegeneration* **13**, 46 (2018).
- 226 17. Zetsche, B. *et al.* Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas
227 System. *Cell* **163**, 759–771 (2015).
- 228 18. Simpson, J. T. *et al.* Detecting DNA cytosine methylation using nanopore sequencing. *Nat*
229 *Methods* (2017). doi:10.1038/nmeth.4184
- 230 19. Boland, M. J. *et al.* Molecular analyses of neurogenic defects in a human pluripotent stem cell
231 model of fragile X syndrome. *Brain* **140**, 582–598 (2017).
- 232 20. Gabrieli, T. *et al.* Selective nanopore sequencing of human BRCA1 by Cas9-assisted targeting
233 of chromosome segments (CATCH). *Nucl. Acids Res.* **46**, e87–e87 (2018).